Arkadios Wealth Advisors Boosts Position in Illumina, Inc. (NASDAQ:ILMN)

Arkadios Wealth Advisors grew its holdings in Illumina, Inc. (NASDAQ:ILMN) by 1.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,833 shares of the life sciences company’s stock after acquiring an additional 131 shares during the period. Arkadios Wealth Advisors’ holdings in Illumina were worth $1,314,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ILMN. Versant Capital Management Inc raised its stake in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares during the last quarter. TD Private Client Wealth LLC raised its position in Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after acquiring an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV lifted its holdings in Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after acquiring an additional 168 shares during the period. Private Trust Co. NA boosted its position in Illumina by 81.2% in the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after purchasing an additional 212 shares in the last quarter. Finally, Focused Wealth Management Inc purchased a new stake in Illumina in the 3rd quarter worth approximately $63,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of analyst reports. Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective for the company in a research report on Thursday, October 17th. Morgan Stanley reduced their price target on Illumina from $156.00 to $150.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Royal Bank of Canada raised their price objective on Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Leerink Partners increased their target price on Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Finally, UBS Group upped their price objective on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Eight investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $165.63.

Illumina Price Performance

NASDAQ:ILMN opened at $136.67 on Monday. The company has a market capitalization of $21.68 billion, a P/E ratio of -13.72 and a beta of 1.11. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66. The stock’s fifty day moving average is $139.60 and its two-hundred day moving average is $133.57.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. Illumina’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.33 earnings per share. Equities analysts expect that Illumina, Inc. will post 4.11 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.